Singapore markets close in 3 hours 55 minutes

Adaptive Biotechnologies Corporation (ADPT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.5900-0.0200 (-0.55%)
At close: 04:00PM EDT
3.5600 -0.03 (-0.84%)
After hours: 06:53PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.6100
Open3.5900
Bid3.5900 x 500
Ask3.6200 x 1000
Day's range3.4900 - 3.6291
52-week range2.2800 - 9.0800
Volume961,520
Avg. volume1,712,022
Market cap529.051M
Beta (5Y monthly)1.27
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Adaptive Biotechnologies Reports First Quarter 2024 Financial Results

    SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2024. “This quarter, we implemented important decisions to maximize the value of our MRD and Immune Medicine businesses. I am confident in the steps w

  • GlobeNewswire

    Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024

    SEATTLE, April 17, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, May 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Ti

  • GlobeNewswire

    Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue

    Announces CFO transitionSEATTLE, April 02, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a business update, including the conclusion of its recent strategic review, preliminary revenue for the first quarter ended March 31, 2024, and transition of the chief financial officer role. Strategic